Clinical-stage biotechnology stocks frequently capture investor attention because their value hinges on clinical milestones, partnership announcements, and capital strength rather than current earnings. CABA and VIR offer a useful stock comparison for traders and investors weighing two contrasting pipelines: an autoimmune-focused cell therapy developer versus a diversified infectious disease and oncology platform. Both have generated substantial year-to-date returns while remaining unprofitable on a full-year basis, making their relative performance a study in how catalysts, cash positions, and momentum shape market positioning. This comparison is most relevant for growth-oriented investors and momentum traders comfortable with binary, data-driven risk.
Cabaletta Bio is a Philadelphia-based, clinical-stage biotechnology company developing engineered T-cell therapies, also known as chimeric antigen receptor T-cell (CAR T) therapies, for B cell-mediated autoimmune diseases. Its lead asset, rese-cel (resecabtagene autoleucel), is being evaluated across multiple autoimmune indications in the RESET clinical program, with pivotal Phase 1/2 data expected around mid-2027 and a potential biologics license application (BLA) submission targeted for late 2027.
Recent weeks have brought meaningful operational progress, including a 10-year commercial manufacturing agreement with Cellares and a $150 million underwritten equity offering that included participation from Eli Lilly. Positive preconditioning-free clinical and translational data were also presented at recent medical meetings. Despite this news flow, the stock experienced a notable pullback from its 2026 highs, reflecting the volatility common to pre-revenue biotechs and some investor concerns about cash consumption and dilution. Insider purchases over the past year have signaled some management confidence, though the share count expansion from recent financings remains a consideration for investors.
Vir Biotechnology is a San Francisco-based, clinical-stage biopharmaceutical company with a pipeline spanning infectious disease and oncology. Its hepatitis delta program, led by the combination of tobevibart and elebsiran, is progressing through the registrational ECLIPSE Phase 3 trials, with top-line data anticipated in late 2026 and early 2027. In parallel, the company is advancing PRO-XTEN dual-masked T-cell engagers (TCEs) for solid tumors, including VIR-5500 in prostate cancer.
Recent market activity has been defined by a string of high-profile partnerships. Vir closed a global strategic collaboration with Astellas valued at up to $1.7 billion centered on VIR-5500, announced a collaboration and license agreement with Gilead Sciences, and received FDA Fast Track designation for VIR-5500. The company reported a swing to quarterly profitability in its most recent quarter, driven largely by upfront collaboration revenue, and ended the first quarter with roughly $809 million in cash, which management expects to fund operations into the second half of 2028. This catalyst-rich period has supported strong year-to-date share-price momentum.
For traders seeking a data-driven edge, Tickeron's Trending AI Robots page offers a curated view of the platform's automated trading strategies. Tickeron hosts hundreds of AI trading bots that monitor thousands of different tickers, each with its own trading style, strategy, timeframe, performance statistics, and universe of securities. Because only the bots best suited to current market conditions are featured, this section helps investors cut through the noise and identify strategies that are actively resonating with prevailing trends. The bots vary widely in approach, from short-term momentum models to longer-horizon trend systems. Readers interested in how automation interprets names like these can explore Trending AI Robots to review the currently featured strategies and their associated metrics.
The two companies diverge most clearly on business model and diversification. Cabaletta's valuation rests heavily on a single lead asset, rese-cel, which concentrates both opportunity and risk in autoimmune cell therapy. Vir, by contrast, balances two therapeutic pillars — hepatitis delta and oncology — and has monetized its platform through multiple collaborations with larger pharmaceutical partners such as Astellas and Gilead.
On growth drivers and catalysts, Vir holds a timing advantage: its ECLIPSE hepatitis delta readouts are expected before Cabaletta's pivotal rese-cel data. On financial positioning, Vir's larger cash balance and extended runway reduce near-term financing risk, whereas Cabaletta has relied on equity raises that dilute existing shareholders. From a momentum and sentiment standpoint, Vir has sustained an uptrend into late 2026, while Cabaletta has corrected despite favorable clinical updates. In terms of risk factors, both face binary clinical outcomes and regulatory uncertainty, but Cabaletta's single-asset profile and higher short interest introduce additional volatility.
Based on observable factors such as trend consistency, catalyst proximity, balance-sheet strength, and relative positioning, Tickeron's AI would likely favor VIR in the current environment. Vir demonstrates steadier price momentum, a more diversified pipeline, nearer-term data catalysts, and a cash runway that reduces immediate financing risk. Cabaletta's autoimmune CAR T platform holds considerable long-term potential, and its recent pullback could appeal to investors with a higher risk tolerance, but its more concentrated asset base and elevated dilution concerns make its trend profile comparatively less stable. This assessment reflects probabilistic analysis of current market positioning rather than a definitive prediction of future returns.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CABA saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned negative. In 82 of the 91 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for CABA turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 44 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CABA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CABA entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +17.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where CABA advanced for three days, in 218 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
CABA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.047) is normal, around the industry mean (3.596). P/E Ratio (-0.942) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. CABA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CABA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
VIR broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 41 similar instances where the stock broke above the upper band. In 39 of the 41 cases the stock fell afterwards. This puts the odds of success at 90%.
The Momentum Indicator moved below the 0 level on November 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VIR as a result. In 72 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
The Moving Average Convergence Divergence Histogram (MACD) for VIR turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 35 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
VIR moved below its 50-day moving average on November 13, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for VIR crossed bearishly below the 50-day moving average on November 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VIR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The RSI Indicator entered the oversold zone -- be on the watch for VIR's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +23.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where VIR advanced for three days, in 205 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.103) is normal, around the industry mean (3.596). P/E Ratio (-6.898) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (5.168) is also within normal values, averaging (443.347).
The Tickeron Seasonality Score of 44 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. VIR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 82 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VIR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
CABA | VIR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 12 | 60 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 51 Fair valued | 19 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 96 | |
PRICE GROWTH RATING 1..100 | 92 | 56 | |
P/E GROWTH RATING 1..100 | 10 | 82 | |
SEASONALITY SCORE 1..100 | n/a | 44 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
VIR's Valuation (19) in the null industry is in the same range as CABA (51). This means that VIR’s stock grew similarly to CABA’s over the last 12 months.
VIR's Profit vs Risk Rating (100) in the null industry is in the same range as CABA (100). This means that VIR’s stock grew similarly to CABA’s over the last 12 months.
VIR's SMR Rating (96) in the null industry is in the same range as CABA (98). This means that VIR’s stock grew similarly to CABA’s over the last 12 months.
VIR's Price Growth Rating (56) in the null industry is somewhat better than the same rating for CABA (92). This means that VIR’s stock grew somewhat faster than CABA’s over the last 12 months.
CABA's P/E Growth Rating (10) in the null industry is significantly better than the same rating for VIR (82). This means that CABA’s stock grew significantly faster than VIR’s over the last 12 months.
| CABA | VIR | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 79% |
| Stochastic ODDS (%) | 2 days ago 81% | 2 days ago 75% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 78% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 83% |
| TrendWeek ODDS (%) | 2 days ago 87% | 2 days ago 81% |
| TrendMonth ODDS (%) | 2 days ago 88% | 2 days ago 78% |
| Advances ODDS (%) | 13 days ago 88% | 13 days ago 76% |
| Declines ODDS (%) | 2 days ago 90% | 2 days ago 81% |
| BollingerBands ODDS (%) | 2 days ago 88% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 86% | N/A |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CABA’s FA Score shows that 1 FA rating(s) are green while VIR’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CABA’s TA Score shows that 4 TA indicator(s) are bullish while VIR’s TA Score has 3 bullish TA indicator(s).
CABA (@Biotechnology) experienced а -26.87% price change this week, while VIR (@Biotechnology) price change was -15.76% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -11.58%. For the same industry, the average monthly price growth was -18.26%, and the average quarterly price growth was -28.15%.
CABA is expected to report earnings on Mar 18, 2027.
VIR is expected to report earnings on Feb 25, 2027.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, CABA has been loosely correlated with EDIT. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if CABA jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To CABA | 1D Price Change % | ||
|---|---|---|---|---|
| CABA | 100% | -7.32% | ||
| EDIT - CABA | 52% Loosely correlated | -4.09% | ||
| FATE - CABA | 50% Loosely correlated | -9.01% | ||
| AURA - CABA | 49% Loosely correlated | -1.58% | ||
| VIR - CABA | 48% Loosely correlated | -5.41% | ||
| NCEL - CABA | 47% Loosely correlated | -8.82% | ||
More | ||||
A.I.dvisor indicates that over the last year, VIR has been loosely correlated with BEAM. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if VIR jumps, then BEAM could also see price increases.
| Ticker / NAME | Correlation To VIR | 1D Price Change % | ||
|---|---|---|---|---|
| VIR | 100% | -5.41% | ||
| BEAM - VIR | 55% Loosely correlated | -0.19% | ||
| BCYC - VIR | 53% Loosely correlated | -4.92% | ||
| CADL - VIR | 53% Loosely correlated | -1.75% | ||
| EDIT - VIR | 52% Loosely correlated | -4.09% | ||
| SLDB - VIR | 52% Loosely correlated | -2.95% | ||
More | ||||